뇌질환을 동반한 과민성방광 환자에서 tolterodine 투여 후 인지기능의 변화
The Change of Cognitive Function after Administration of Tolterodine in Brain Disease Patients with Overactive Bladder
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Puropose: It is known that anticholinergics induces cognitive dysfunction and may aggravate the state of it. Tolterodine tartrate (detrusitolⓇ) is a widely known selective anticholinergics to bladder, which does not cause a cognitive dysfunction. This study was designed to analyze the change of cognitive function of brain disease patients, whom are taking anticholinesterase inhibitor with tolterodine for overactive bladder (OAB). Material and methods: From January 2001 to December 2004, with the patients whom have been followed for the brain disease in the department of neurology, we have analyzed 79 patients with tolterodine administered for OAB. We used K-MMSE (Korea minimental status examination) and SNSB (seoul neuropsychological screening battery) to analyze the state of cognition. Mean age of patients was 67.3±4.5 (yrs), mean administration period was 4.7±9.5 (mon). Results: 7 patients made complaints for the decline of memory, 2 of them with Parkinsonism and 2 with cerebral infarction, 1 with progressive supranuclear palsy and, 2 dementia with lewy body (DLB). Patients with DLB was excluded in this study because the disease had fluctuation of cognitive function. Conclusions: The result of these studies demonstrates tolterodine tartrate caused the decline of cognitive function in only a few patients with brain disease. We concluded that prospective studies are needed to change the cognitive functions of the brain disease patients with OAB after administration of tolterodine tartrate. (J Korean Continence Soc 2008;12:133-8)
참고문헌 (26)
- Abrams P, "The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society", Urology, 61, pp.37~49 (2003)
- Milsom I, "How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study", BJU Int, 87, pp.760~766 (2001)
- Rovner ES, "Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: A review", Eur Urol, 41, pp.6~14 (2002)
- Caulfield MP, "International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors", Pharmacol Rev, 50, pp.279~290 (1998)
- Kopelman MD, "The cholinergic neurotransmitter system in human memory and dementia: A review", Q J Exp Psychol A, 38, pp.535~573 (1986)
- Morrison RL, "Drug-related cognitive impairment: Current progress and recurrent problems", Annu Rev Gerontol Geiatr, 9, pp.232~279 (1989)
- Katz IR, "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride", J Am Geriatr Soc, 46, pp.8~13 (1998)
- Bedard MA, "Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcortico-frontal syndrome", Brain Cogn, 40, pp.289~313 (1999)
- Agnoli A, "Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer’s dementia: a neuropsychological and computerized electroencephalographic study", Clin Neuropharmacol, 6, pp.311~323 (1983)
- Kang Y, "A validity study on the korean mini mental state examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Na DL, "Neuropsychological Screening Battery" (2003), Human Brain Research & Conculting Co
- Himashree G, "Sleep and performance-recent trends", Indian J Physiol Pharmacol, 46, pp.6~24 (2002)
- Brown JS, "Urinary incontinence: Dose it increase risk for falls and fractures?", J Am Geriatr Soc, 48, pp.721~725 (2000)
- Moore AR, "Drug-induced cognitive impairment in the elderly", Drugs Aging, 15, pp.15~28 (1999)
- Tune LE, "Anticholinergic effects of medication in elderly patients", J Clin Psychiatry, 62, pp.11~14 (2001)
- Blazer DG II, "Schaffner W. The risk of anticholinergic toxicity in the elderly: A study of prescribing practices in two populations", J Gerontol, 38, pp.31~35 (1983)
- Hasselmo ME, "Free recall and recognition in a network model of the hippocampus: simulating effects of scopolamine on human memory function", Behav Brain Res, 89, pp.1~34 (1997)
- Pak RW, "Trospium chloride: A quaternary amine with unique pharmacologic properties", Curr Urol Rep, 4, pp.436~440 (2003)
- Todorova A, "Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system", J Clin Pharmacol, 41, pp.636~644 (2001)
- Brynne N, "Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine", Clin Pharmacol Ther, 63, pp.529~539 (1998)
- Malone-Lee JG, "Tolterodne: A safe and effective treatment for older patients with overactive bladder", J Am Geriatr Soc, 49, pp.700~705 (2001)
- Appell RA, "Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the object study", Mayo Clin Proc, 76, pp.358~363 (2001)
- Homma Y, "for the Japanese and Korean tolterodine study group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial", BJU Int, 92, pp.741~747 (2003)
- Womack KB, "Tolterodine and memory: dry but forgetful", Arch Neurol, 60, pp.771~773 (2009)
- Anagnostaras SG, "Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor-mutant mice", Nat Neurosci, 6, pp.51~58 (2003)
- Morris JC, "The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's diasease", Neurology, 43, pp.2457~2465 (1993)